Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Alrn-6924, a Dual Inhibitor of MDMX and MDM2, Transiently Induces Cell Cycle Arrest in Bone Marrow and Prevents Toxicity in Mouse Models of Acute Radiation Injury

Allen Annis, David Sutton, Manuel Aivado, Vojislav Vukovic

Blood (2021) 138 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2021-153206

Published: 2021

Journal Articles

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

Andrei R. Shustov, MD, Steven M. Horwitz, MD, Jasmine Zain, MD, Manish R Patel, MD, Sanjay Goel, MD, Lubomir Sokol, MD PhD, Funda Meric-Bernstam, MD, Geoffrey Shapiro, MD PhD, Sunita Dwivedy Nasta, MD, Murali Janakiram, MD MS, David M Weinstock, MD, Ronald Korn, MD PhD, Marie Payton, MBA, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Amitkumar Mehta, MD

Blood (2018) 132 (Supplement 1): 1623.

https://doi.org/10.1182/blood-2018-99-116780

Published: 2018

Journal Articles

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

David A Sallman, MD, Uma Borate, MD, Elizabeth H. Cull, MD, William B. Donnellan, MD, Rami S. Komrokji, MD, Ulrich G. Steidl, MD PhD, Maria M Corvez, Marie Payton, MBA, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Amit Verma, MD

Blood (2018) 132 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2018-99-118780

Published: 2018

Journal Articles

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

Andrei R. Shustov, MD, Amitkumar Mehta, MD, Lubomir Sokol, MD PhD, Luis A. Carvajal, PhD, Vincent Guerlavais, PhD, Manoj Samant, PhD, Narayana Narasimhan, PhD, David Sutton, BSc, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Ronald Korn, MD PhD

Blood (2018) 132 (Supplement 1): 5348.

https://doi.org/10.1182/blood-2018-99-119489

Published: 2018

Journal Articles

Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Luis A. Carvajal, PhD, Daniela Ben-Neriah, B.S, Adrien Senecal, PhD, Lumie Bernard, M.S, Swathi-Rao Narayanagari, M.S, Charles Kenworthy, B.S, Victor Thiruthuvanathan, M.S, Vincent Guerlavais, PhD, D. Allen Annis, PhD, Boris Bartholdy, PhD, Britta Will, PhD, Jesus Anampa, MD, Ioannis Mantzaris, MD, Manuel A. Aivado, MD PhD, Robert H Singer, PhD, Robert Coleman, PhD, Amit Verma, MD, Ulrich G. Steidl, MDPhD

Blood (2017) 130 (Supplement 1): 795.

https://doi.org/10.1182/blood.V130.Suppl_1.795.795

Published: 2017

Journal Articles

Stapled Peptides: Leveraging the BH3 α-Helix to Create a New Class of Drugs to Treat Hematological Malignancies

Rosana Kapeller, Jiawen Han, Kaiming Sun, Pranoti Gangurde, Nori Kawahata, Matt Iadanza, Vincent Guerlevais, Jim Horstick, Justin Noehre, Allen Annis, Larry Licklider, Huw M. Nash, Andrew Kung, Tomi K. Sawyer

Blood (2008) 112 (11): 2929.

https://doi.org/10.1182/blood.V112.11.2929.2929

Published: 2008

NARROW

Alrn-6924, a Dual Inhibitor of MDMX and MDM2, Transiently Induces Cell Cycle Arrest in Bone Marrow and Prevents Toxicity in Mouse Models of Acute Radiation Injury

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Stapled Peptides: Leveraging the BH3 α-Helix to Create a New Class of Drugs to Treat Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Alrn-6924, a Dual Inhibitor of MDMX and MDM2, Transiently Induces Cell Cycle Arrest in Bone Marrow and Prevents Toxicity in Mouse Models of Acute Radiation Injury

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Stapled Peptides: Leveraging the BH3 α-Helix to Create a New Class of Drugs to Treat Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only